Genmab Reports 28.2-Month Median Overall Survival in Phase 2 Study
Genmab reported median overall survival of 28.2 months with petosemtamab plus pembrolizumab in a Phase 2 study.
Related stories
Reliance Industries Q2 Profit May Top Rs 21,000 Crore
Reliance Industries is expected to report September-quarter profit above Rs 21,000 crore, with refining and Jio cited as earnings drivers. The company is scheduled to announce resu
M impact | EQUITY | Oct 30, 2026, 04:11 AM UTC
Australian Energy Stocks Reach One-Week High as Oil Rises
Australian energy stocks reached a one-week high as supply concerns lifted oil prices.
M impact | EQUITY | Oct 30, 2026, 04:03 AM UTC
Nasdaq 100 futures fall 2%; S&P 500 futures down almost 1%
M impact | EQUITY | Oct 30, 2026, 04:03 AM UTC
U.S. Stock Futures Fall as Intel and Amazon Earnings Weigh
At 11:44 p.m. EDT, Dow futures fell 0.17%, S&P 500 futures fell 0.95% and Nasdaq-100 futures fell more than 2% after disappointing earnings from Intel and Amazon.
M impact | EQUITY | Oct 30, 2026, 04:03 AM UTC
Janome to Buy Back Up to 5.98% of Shares
L impact | EQUITY | Oct 30, 2026, 04:02 AM UTC
Asian session market picture: S&P 500 -0.94%, Nasdaq 100 -2.06%; USD/JPY -0.15%, WTI +1.18%, 1810 leads volume
Asian session market picture. US index futures: S and P futures is down 0.94 percent, Nasdaq futures is down 2.06 percent, Dow futures is down 0.19 percent and Russell futures is d
M impact | EQUITY | Oct 30, 2026, 04:00 AM UTC